SCHEMBL296548

SCHEMBL296548

O=C(C=Cc1ccn(S(=O)(=O)c2cccc(-c3ccccc3)c2)c1)NO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 18/20 0.55
HDAC6 Q9UBN7 17/20 0.55
HDAC8 Q9BY41 17/20 0.55
HDAC2 Q92769 17/20 0.55
HDAC3 O15379 16/20 0.55
HDAC4 P56524 15/20 0.55
HDAC7 Q8WUI4 15/20 0.55
HDAC10 Q969S8 15/20 0.55
HDAC11 Q96DB2 15/20 0.55
HDAC9 Q9UKV0 15/20 0.55
HDAC5 Q9UQL6 15/20 0.55
BRD4 O60885 1/20 0.50
ESR1 P03372 1/20 0.50
PTGS1 P23219 1/20 0.50
PDE4A P27815 1/20 0.50
PIK3CA P42336 1/20 0.50
HTR6 P50406 1/20 0.50
PDE4D Q08499 1/20 0.50
ASPH Q12797 1/20 0.50
ABL1 P00519 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296547 1.00 HDAC1 (0.55) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL3145473 0.92 HDAC1 (0.51) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL3145488 0.92 HDAC1 (0.51) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL296243 0.91 HDAC1 (0.52) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL296244 0.91 HDAC1 (0.52) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL3853243 0.91 HDAC1 (0.49) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL3146007 0.89 HDAC1 (0.58) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL3146017 0.89 HDAC1 (0.58) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL296490 0.89 HDAC1 (0.65) HDAC1HDAC6HDAC8HDAC2HDAC3
SCHEMBL295857 0.89 HDAC1 (0.43) HDAC1HDAC6HDAC8HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP claimed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US claimed
US-8067615-B2 Sulphonylpyrroles 4SC AG (DE) 2011-11-29 US claimed
US-20110166140-A1 NOVEL SULPHONYLPYRROLES MAIER THOMAS 2011-07-07 US claimed
US-20100261761-A1 Novel Sulfonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20100261721-A1 Novel Sulphonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 US claimed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
WO-2019043176-A2 HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY 4SC AG (DE) 2019-03-07 WO disclosed
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 US disclosed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP disclosed
EP-1928826-B1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS 4SC AG (DE) 2013-04-24 EP disclosed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US disclosed
EP-1928872-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES Nycomed GmbH (DE) 2008-06-11 EP disclosed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 US disclosed
WO-2007039404-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES NYCOMED GMBH (DE) 2007-04-12 WO disclosed
WO-2007039403-A1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS NYCOMED GMBH (DE) 2007-04-12 WO disclosed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184979-A1 Novel sulfonylpyrroles HDAC1, HDAC4, HDAC3 HDAC1 1/4885HDAC6 8/4885HDAC8 9/4885
US-20110166140-A1 NOVEL SULPHONYLPYRROLES HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC6 7/4885HDAC8 11/4885
US-20100261761-A1 Novel Sulfonylpyrroles HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-20100261721-A1 Novel Sulphonylpyrroles HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC6 7/4885HDAC8 11/4885
US-20130079347-A1 NOVEL SULFONYLPYRROLES HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.